Filing Flows

Filing Flows › Immunome (IMNM) › Who owns the stock

Who owns Immunome (IMNM) stock

193 funds reported Immunome (IMNM) shares in their latest 13F filings, worth $2.6B in all. The largest holder is T. Rowe Price Investment Management ($417M). Last quarter 97 funds added to their stakes and 78 cut them.

Largest holders of IMNM (13F)Largest holders of IMNM (13F)T. Rowe Price Investment Manageme…$417MFMR LLC$360MBlackRock$187MVanguard Group$130MState Street$116MWellington Management Group LLP$110MRedmile Group, LLC$104MPrimecap Management$97.1MVanguard Capital Management LLC$96.4MDriehaus Capital Management LLC$92.1M

Largest holders (13F)

FundSharesValueChangeQuarter
T. Rowe Price Investment Management19,676,883$417Mincrease2026-06-30
FMR LLC16,987,553$360Mincrease2026-06-30
BlackRock8,805,492$187Mincrease2026-06-30
Vanguard Group6,038,414$130Mincrease2025-12-31
State Street5,494,625$116Mincrease2026-06-30
Wellington Management Group LLP5,210,216$110Mincrease2026-06-30
Redmile Group, LLC4,911,590$104Mdecrease2026-06-30
Primecap Management4,581,431$97.1Mdecrease2026-06-30
Vanguard Capital Management LLC4,551,289$96.4Mincrease2026-06-30
Driehaus Capital Management LLC4,346,139$92.1Mincrease2026-06-30
Enavate Sciences GP, LLC3,613,799$76.6Munchanged2026-06-30
Geode Capital Management, LLC2,754,889$58.4Mincrease2026-06-30
Morgan Stanley2,407,942$51.0Mdecrease2026-06-30
Silverarc Capital Management, LLC2,017,009$42.7Mincrease2026-06-30
Price T Rowe Associates1,773,229$37.6Mdecrease2026-06-30

Immunome's latest quarter

Immunome, Q2 2025: revenue $4.0M (+70% year over year), net loss $43.4M, operating cash flow −$49.4M. The chart follows the revenue to costs, profit and cash.

Questions

Who owns the most IMNM stock?

By the latest 13F filings: T. Rowe Price Investment Management ($417M); FMR LLC ($360M); BlackRock ($187M); Vanguard Group ($130M); State Street ($116M).

What is the short interest in IMNM?

17,281,614 shares were sold short at the 2026-10-15 settlement, 3.13% of the float.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.